EFFICACY AND SAFETY OF SEMAGLUTIDE IN THE TREATMENT OF OBESITY IN ADULTS: A LITERATURE REVIEW

Main Article Content

Ednatalia Barbada da Silva
Melissa de Moura e Silva
Victor Augusto Araújo Barbosa

Abstract

Obesity is a multifactorial condition and a major global public health issue, associated with increased morbidity and mortality and with a higher risk of chronic diseases such as type 2 diabetes, hypertension and cardiovascular disorders. Among emerging pharmacological approaches for its management, semaglutide a glucagon-like peptide-1 (GLP-1) receptor agonist stands out due to its effectiveness in reducing appetite, delaying gastric emptying and promoting significant weight loss. This study aimed to analyze, through an integrative literature review, the available scientific evidence regarding the efficacy and safety of semaglutide in the treatment of obesity in adults. This qualitative research was conducted using studies indexed in PubMed, SciELO and LILACS, published between 2017 and 2025, using descriptors related to semaglutide, obesity and GLP-1. The findings indicate that semaglutide leads to substantial weight loss, improvement of metabolic parameters and a favorable safety profile, predominantly characterized by mild gastrointestinal adverse events. However, continuous monitoring and combined interventions are essential to maintain treatment outcomes in the long term. This review is expected to contribute to clinical practice by providing updated evidence and enhancing understanding of the safe and effective use of semaglutide in obesity management. 

Article Details

Section

Artigos